Cancer patients who enroll in a clinical trial and have no health insurance, or are enrolled in Medicaid may not get the same benefits of successful trial treatments that other cancer patients do.
Mount Sinai researchers have found a new type of therapy to be effective for patients with a particular type of bone marrow cancer that is resistant to several standard therapies, according to results of a clinical trial published in The New England Journal of Medicine in August.
GlaxoSmithKline plc announced positive results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916).
The Genomics of Drug Sensitivity in Cancer project has released the results of four years of data gathering and exploration. The freely available data set includes unique data comparing almost 1,000 cancer cell lines' responses to 453 licensed and experimental drugs.
Vermillion Inc. announced publication of a paper titled: “Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays for Presurgical Assessment for Ovarian Cancer Risk” in the journal Advanced Therapeutics (Shulman et al. Adv Ther. July 2019).
Invitae announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.
A research team led by investigators from Georgetown University Medical Center and Fudan University in China, has devised a non-invasive and individualized technique for detecting and treating bladder cancer.
Paige.AI announced the publication of an article in Nature Medicine describing an AI system for computational pathology that achieves clinical-grade accuracy levels.
Elios Therapeutics announced positive top-line results from the prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial evaluating its lead immuno-oncology candidate, TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with stage 3 and 4 resected melanoma.
Intensity Therapeutics Inc. announced the publication in the journal OncoImmunology of results from nonclinical research conducted in partnership with NCI Vaccine Branch under a Cooperative Research and Development Agreement. All results and data reported in the paper were generated at the NCI.
